Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

PURPOSE: New treatments are needed for patients with fludarabine- and alemtuzumab-refractory (FA-ref) chronic lymphocytic leukemia (CLL) or patients with fludarabine-refractory CLL with bulky (> 5 cm) lymphadenopathy (BF-ref) who are less suitable for alemtuzumab treatment; these groups have poor...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Wierda, William G., Kipps, Thomas J., Mayer, Jiří, Stilgenbauer, Stephan, Williams, Cathy D., Hellmann, Andrzej, Robak, Tadeusz, Furman, Richard R., Hillmen, Peter, Trneny, Marek, Dyer, Martin J.S., Padmanabhan, Swami, Piotrowska, Magdalena, Kozak, Tomas, Chan, Geoffrey, Davis, Randy, Losic, Nedjad, Wilms, Joris, Russell, Charlotte A., Österborg, Anders
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2010
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979101/
https://ncbi.nlm.nih.gov/pubmed/20194866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.3187
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi